The aim of this study was to evaluate the efficiency and safety of single-agent bevacizumab therapy for recurrent glioblastoma multiforme (GBM). The data suggest that improvement in performance status (IPS) following bevacizumab therapy was a significant predictor of both PFS and OS.

The authors identified patients with histologically confirmed glioblastoma and World Health Organization Grade III glioma who were previously treated with temozolomide plus radiotherapy and received 10 mg/kg bevacizumab intravenous infusion every 2 weeks until disease progression for recurrent disease.

Univariate analysis showed that improvement in performance status (IPS) following bevacizumab therapy was a significant predictor of both PFS (p < 0.001) and OS (p < 0.020).

This article originally appeared on Cancer Therapy Advisor

READ FULL ARTICLE Curated publisher From Mdlinx